InfuSystem (INFU) Stock Price, News & Analysis

Company Overview

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Key Stats

• Today's Range: $7.65 to $8.89
• 50-Day Range: $5.41 to $8.83
• 52-Week Range: $4.61 to $9.97
• Volume: 654,482 shs
• Average Volume: 157,035 shs
• Market Capitalization: $185.57 million
• P/E Ratio: 147.19
• Dividend Yield: N/A
• Price Target: $12.50
• Consensus Rating: Strong Buy

InfuSystem Stock Analysis - MarketRank™

InfuSystem scored higher than 60% of companies evaluated by MarketBeat, and ranked 352nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

InfuSystem has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 106.67%

Earnings Growth

Earnings for InfuSystem are expected to grow by 106.67% in the coming year, from $0.15 to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InfuSystem is 147.19, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of InfuSystem is 147.19, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.95.

Price to Book Value per Share Ratio

InfuSystem has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.88% of the float of InfuSystem has been sold short.

Short Interest Ratio / Days to Cover

InfuSystem has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InfuSystem has recently increased by 5.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InfuSystem does not currently pay a dividend.

Dividend Growth

InfuSystem does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.88% of the float of InfuSystem has been sold short.

Short Interest Ratio / Days to Cover

InfuSystem has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InfuSystem has recently increased by 5.76%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.59

News Sentiment

InfuSystem has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for InfuSystem this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for INFU on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added InfuSystem to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, InfuSystem insiders have bought more of their company's stock than they have sold. Specifically, they have bought $46,629.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

11.40% of the stock of InfuSystem is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.13% of the stock of InfuSystem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INFU Stock Analysis - Frequently Asked Questions

How have INFU shares performed this year?

InfuSystem's stock was trading at $8.45 at the beginning of the year. Since then, INFU shares have increased by 4.5% and is now trading at $8.83.

How were InfuSystem's earnings last quarter?

InfuSystem Holdings, Inc. (NYSE:INFU) released its earnings results on Thursday, November, 7th. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.08. The business earned $35.32 million during the quarter, compared to analyst estimates of $35.50 million. InfuSystem had a net margin of 1.12% and a trailing twelve-month return on equity of 2.78%.

Who are InfuSystem's major shareholders?

InfuSystem's top institutional shareholders include First Eagle Investment Management LLC (4.33%), Geode Capital Management LLC (1.06%), Connor Clark & Lunn Investment Management Ltd. (0.33%) and Y Intercept Hong Kong Ltd (0.22%). Insiders that own company stock include Richard Dilorio, Carrie Lachance, Christopher R Sansone, Barry G Steele, Paul Andrew Gendron, R Rimmy Malhotra, Addam Chupa, Kenneth D Eichenbaum, Ralph F Boyd Jr, Kevin Whitman and Gregg Owen Lehman.
View institutional ownership trends.

How do I buy shares of InfuSystem?

Shares of INFU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InfuSystem own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InfuSystem investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 8/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:INFU
• Previous Symbol: NYSE:INFU
• CIK: 1337013
• Web: www.infusystem.com
• Phone: (248) 291-1210
• Fax: 800-455-4338
• Employees: 410
• Year Founded: N/A

Price Target and Rating

• Average Price Target for InfuSystem: $12.50
• High Price Target: $13.00
• Low Price Target: $12.00
• Potential Upside/Downside: +41.6%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 4.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.23
• Trailing P/E Ratio: 147.19
• Forward P/E Ratio: 58.87
• P/E Growth: N/A
• Net Income: $870 thousand
• Net Margins: 1.12%
• Pretax Margin: 2.65%
• Return on Equity: 2.78%
• Return on Assets: 1.41%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.98
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $139.89 million
• Price / Sales: 1.33
• Cash Flow: $0.69 per share
• Price / Cash Flow: 12.79
• Book Value: $2.47 per share
• Price / Book: 3.57

Miscellaneous

• Outstanding Shares: 21,016,000
• Free Float: 19,095,000
• Market Cap: $185.57 million
• Optionable: Optionable
• Beta: 1.81